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A stepped wedge trial of efficacy and
scalability of a virtual clinical pharmacy
service (VCPS) in rural and remote NSW
health facilities
Julaine Allan1*, Shannon Nott2, Brett Chambers2, Ged Hawthorn2, Alice Munro2, Chris Doran3, Chris Oldmeadow4,
Clare Coleman2 and Teesta Saksena2
Abstract
Background: Medication errors are a leading cause of mortality and morbidity. Clinical pharmacy services provided
in hospital can reduce medication errors and medication related harm. However, few rural or remote hospitals in
Australia have a clinical pharmacy service. This study will evaluate a virtual clinical pharmacy service (VCPS) provided
via telehealth to eight rural and remote hospitals in NSW, Australia.
Methods: A stepped wedge cluster randomised trial design will use routinely collected data from patients’
electronic medical records (n = 2080) to evaluate the VCPS at eight facilities. The sequence of steps is randomised,
allowing for control of potential confounding temporal trends. Primary outcomes are number of medication
reconciliations completed on admission and discharge. Secondary outcomes are length of stay, falls and 28 day
readmissions. A cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA) will be conducted. The CEA will
answer the question of whether the VCPS is more cost-effective compared to treatment as usual; the CBA will
consider the rate of return on investing in the VCPS. A patient experience measure (n = 500) and medication
adherence questionnaire (n = 100 pre and post) will also be used to identify patient responses to the virtual service.
Focus groups will investigate implementation from hospital staff perspectives at each site.
Analyses of routine data will comprise generalised linear mixed models. Descriptive statistical analysis will
summarise patient experience responses. Differences in medication adherence will be compared using linear
regression models. Thematic analysis of focus groups will identify barriers and facilitators to VCPS implementation.
Discussion: We aim to demonstrate the effectiveness of virtual pharmacy interventions for rural populations, and
inform best practice for using virtual healthcare to improve access to pharmacy services. It is widely recognised that
clinical pharmacists are best placed to reduce medication errors. However, pharmacy services are limited in rural
and remote hospitals. This project will provide evidence about ways in which the benefits of hospital pharmacists
can be maximised utilising telehealth technology. If successful, this project can provide a model for pharmacy
delivery in rural and remote locations.
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Background
Globally, medication errors are a leading cause of avoid-
able morbidity and mortality with an estimated cost of
$42 billion annually [1]. Hospital pharmacists play a key
role in reducing medication errors through medication
reconciliation [2–5]. Medication reconciliation (Med
Rec) is the process of ensuring that patients receive pre-
scribed medicines and that accurate, current and com-
prehensive medicines information follows them at all
transfers of care. In hospitals, Med Rec has been reliably
found to improve medication safety [6–11] and has been
identified as an international priority by the World
Health Organization [2, 6, 12].
In Australia medication safety is addressed through
Standard 4 of the National Safety & Quality Health Ser-
vice Standards (NSQHS) which includes safe prescribing,
dispensing, administering and monitoring of appropriate
medicines to informed patients [13]. However,
medication-related incidents are the second most fre-
quently reported incidents in NSW hospitals [14]. Con-
sequently, improved medication management is a high
priority, particularly in rural and remote settings where
clinical pharmacy services are limited.
Australian research indicates that patients’ problems
understanding and using their medications increases the
risk of readmission 2.3 times [8, 15]. Integrating clinical
pharmacists into hospital settings improves medication
management, reduces medication harm, supports pa-
tients and decreases unwarranted clinical variation [16].
However, there is limited provision of Med Rec in rural
Australian hospitals due to few on-site pharmacists [17–
20] consequently patients are at a higher risk for
medication-related harms [21]. Virtual or telehealth
pharmacy services are one option to address the lack of
on-site pharmacists.
Virtual pharmacy services have been implemented
across parts of rural and remote Australia, particularly
Queensland, however much of the literature reports on
outpatient medication reviews rather than inpatient ser-
vices [16, 22–24]. A feasibility study evaluating a service
providing virtual clinical pharmacy reviews for inpatients
in rural and remote regions was found to be acceptable
[23]. Despite this, few studies have since reviewed ser-
vice efficacy, with most studies focussing on patient sat-
isfaction [23]. The use of virtual service delivery has
been demonstrated to increase accessibility to specialist
care particularly for rural and remote populations in-
cluding Aboriginal communities, with evidence support-
ing the use of virtual technologies for the management
of chronic diseases [25].
Three small studies have assessed the feasibility and
acceptability of virtual pharmacy services in rural and re-
mote locations [16, 23, 24]. This study will add to exist-
ing literature to provide evidence about the feasibility
and efficacy of virtual pharmacy services in relation to
patient outcomes, patient experience and economic
factors.
The VCPS evaluation aims to 1.) Investigate if the
VCPS results in a detection of preventable medication
harms, reductions of readmission, falls and length of
stay; 2.) Identify if the VCPS is cost-effective; and 3.) As-
sess if the VCPS is perceived to be an acceptable service
for patients and clinicians.
Western NSW Local Health District (WNSWLHD)
and Far West Local Health District (FWLHD) comprise
some of the most remote regions in NSW, Australia.
The two districts cover almost 450,000km2 with a popu-
lation of 300,000 people. Services are provided by a com-
bination of rural referral hospitals, rural hospitals,
multipurpose facilities and nurse-only remote clinics.
Onsite clinical pharmacy services are provided to only
seven of thirty eight facilities, resulting in noncompli-
ance with Standard 4 of the National Safety & Quality
Health Service Standards (NSQHS) [13]. Existing tele-
health infrastructure along with recent roll out of elec-
tronic medication management (eMeds) in the
electronic medical record (eMR), has provided the infra-
structure for a virtual clinical pharmacy service (VCPS).
Methods/design
The VCPS evaluation will employ a stepped wedge clus-
ter randomised trial design, where the intervention is se-
quentially implemented at eight facilities. The ‘steps’ are
the order in which these sites cross-over from the con-
trol condition (pre-VCPS) to the intervention condition
(VCPS). The sequence of the steps is randomised, allow-
ing for control of potential confounding temporal trends.
The cross-over will occur across 8 waves or steps (one
site per step), each 1 month apart with a 2 month ‘in-
transition’ period (see Fig. 1).
Allan et al. BMC Health Services Research          (2020) 20:373 Page 2 of 8
The virtual pharmacy service will be delivered in six
rural NSW hospitals that do not have an on-site
pharmacist but are using electronic medication manage-
ment and patient record systems and have more than
twenty inpatient admissions per month; and two remote
hospitals that have between seven and thirteen admis-
sions per month and fit the other inclusion criteria. All
adult patients of emergency departments and inpatient
wards of the participating hospitals will be included in
the study. The order of the site implementation will be
determined by computer-generated random numbers.
The intervention will consist of utilising the eMR,
eMeds and a wireless teleconferencing cart with two–
way audio and visual called a ‘Wallie’ to provide clinical
pharmacy services to study sites. Virtual Pharmacists will
work 8.30 am to 4.30 pm, Monday-Friday of each week
over the study period where it is anticipated they will
see up to ten patients per pharmacist per day.
Virtual clinical pharmacists will conduct Med Rec on
admission, discharge or transfer and document a medi-
cation history in eMeds. A summary of the Med Rec and
any identified issues will be documented on the eMR
Medication Management Plan. To ensure continuity of
medication management on discharge back to the com-
munity, the pharmacist will provide an updated medica-
tion list on discharge. The virtual pharmacist will
provide comprehensive information to the patient or
carer to enable safe and effective use of the medications.
This will be tailored to suit the patient’s individual cir-
cumstances and may be in the form of verbal instruc-
tions, demonstration, education, a medication list,
written advice or a consumer medicines information
sheet. Pharmacists will also undertake clinical medica-
tion review for inpatients of the facilities and provide
medication advice to Doctors and Nurses. Any harms or
clinical incidents arising from the VCPS will be ad-
dressed using the NSW Health Incident Management
System (IMS) and investigations will be conducted ac-
cording to clinical governance processes.
Routinely collected, de-identified health data will be
analysed pre and post VCPS (see Table 1). Data will be
collected from the electronic medical record and Health
Intelligence Unit (HIU) reports. A waiver of consent has
been granted for this de-identified data. Patients receiv-
ing the service will be invited by nursing staff at their fa-
cility to complete a patient experience measure and a
medication non-adherence questionnaire [26]. Staff at
participating hospitals will be invited by email from the
research team to a focus group about their experience of
the virtual pharmacy service. Participation will be volun-
tary and written consent required.
The primary outcome variables are: 1) the proportion
of separations (“discharged home by the hospital”) where
the medication reconciliation occurred on admission;
and 2) the proportion of separations (“discharged home
by the hospital”) where the medication reconciliation oc-
curred on discharge. Secondary outcome variables in-
clude 28-day readmission, hospital length of stay (LOS),
number of falls and detection of medication-related er-
rors. Our analyses will comprise generalised linear mixed
models, with fixed effects for time, period (pre vs post),
and patient-level confounding variables, as well as ran-
dom effects for facility and patient to model clustering/
repeat measures. Analyses will exclude separations
where the patient is transferred to another facility.
Sample size: Across the eight sites a referral rate of 29
patients per month is estimated yielding approximately
2088 patients over the intervention period. Assuming a
Fig. 1 VCPS stepped wedge cluster randomised control trial design. There are a total of 8 steps, with each step being one month apart. The light
blue represent sites unexposed to the intervention (control). White represents sites where the service is being introduced and no data will be
used in the analysis. Dark blue represents sites exposed to the VCPS, and purple the service continuation and evaluation
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baseline medication reconciliation rate on admission of
11% (a similar rate for discharge medication reconcilia-
tions), an intra-class correlation of 0.05, and an average
of 29 patient separations per site per month,) there will
be over 90% power to detect an absolute 10% increase in
the proportion of reconciliations performed on admis-
sion and discharge, with a type 1 error rate of 2.5%.
A PREMS will be conducted with patients who have
seen the virtual pharmacist. The PREM survey consists
of 10 questions which will be delivered while the patient
is in hospital using a tablet device and the Customer
Feedback Solutions electronic system. The PREMS will
be delivered electronically via Customer Feedback Sys-
tems (CFS). CFS will securely store the results and pro-
vide de-identified reports monthly.
The PREMS will be used to quantitatively assess im-
provements in patients’ knowledge and perceived accept-
ability of virtual pharmacy. The VCPS questions address
patient communication of medication management dur-
ing hospital admission, patient’s confidence managing
medications and overall satisfaction with the VCPS.
To evaluate the acceptability of VCPS against face to
face pharmacy services, PREMS will be conducted on
the general medical wards at two hospitals with patients
who have seen a face to face inpatient pharmacist. The
general medical ward was chosen as it will have the most
similar patient population to the study sites. Data will be
collected from the comparison sites between May 2020
and June 2021.
All inpatients receiving the VCPS will be invited to
complete the PREMS (estimated n = 500). All inpatients
receiving an inpatient face to face pharmacy service on
the medical wards at two comparison hospitals within a
3 month time period (to be negotiated with the sites) be-
tween March 2020 and June 2021 will be asked to
complete the PREMS (estimated n = 500). A sample of
this size will allow detection of differences in responses
between demographic sub-groups of at least 0.3 standard
deviations (i.e. a moderate effect size), with 90% power
and 5% type 1 error rate. Descriptive statistical analysis
will summarise patient answers, and linear regression
models will be used to explore characteristics associated
with the overall score using age, sex and Aboriginality as
independent variables.
Medication adherence refers to whether a patient takes
their medications as prescribed and is a primary deter-
minant of treatment success. Poor adherence to medica-
tions is common in patients with chronic disease and in
patients prescribed preventative medications. The 26
question Voil’s Medication non-adherence questionnaire
Table 1 Measures and routinely collected data source for VCPS evaluation
Outcome Measure Data Source Level of Data
% medication reconciliation on admission eMR Report EM002 Facility
% medication reconciliation on discharge eMR Report EM002 Facility
VTE Prophylaxis rates Audit Office report Facility
Antimicrobial usage iPharmacy Dispensing Software Facility
% medication list on discharge Custom eMR report Patient
28 day readmission HIU report Facility
28 day readmission Aboriginal patients HIU report Facility
Length of stay HIU report Facility
Length of stay Aboriginal patients HIU report Facility
Falls HIU report Facility
Detection of preventable medication errors HIU report Facility
Economic analysis (cost effectiveness) & scalability HIU reports Facility
Process Measure Data Source Level of Data
Number of medication reconciliation completed eMR report EM002 Facility
Number of medication lists on discharge Custom eMR report Patient
Number of referrals/ number of referrals completed eMR report PC011 Patient
Pharmacist Interventions eMR DA2 Clinical Pharmacy Interventions Patient
Time taken to undertake interventions eMR DA2 Clinical Pharmacy Interventions Patient
Time taken to provide education eMR DA2 Clinical Pharmacy Interventions Patient
Number of consultations eMR report PC011 Patient
Uptake of pharmacy recommendations eMR DA2 Clinical Pharmacy Interventions Patient
Number of pharmacist AMS reviews eMR report PC011/ eMR Report EM008 Patient
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(Voil’s) is validated to identify non-adherence behaviour
in a number of chronic disease populations and scores
have been show to correlate well with objective mea-
sures and clinical outcomes [26]. The measure records
reasons for nonadherence. This is important in a rural
and remote setting where availability of medication may
be limited or the cost prohibitive. Identifying the reasons
for non-adherence allows interventions to be tailored to
those.
The Voil’s will be administered to patients on admis-
sion to study sites in both control and intervention pe-
riods electronically via Customer Feedback Systems
(CFS). CFS will securely store the results and provide
de-identified reports monthly. The Voil’s will then be re-
peated 4 weeks post discharge to assess changes in medi-
cation adherence due to the VCPS. A follow-up survey
will be administered via text message invitation request-
ing the patient complete the questionnaire electronically
via the Customer Feedback Systems platform. A sample
of 75 patients in the pre period and 75 patients in the
post period (across all sites) will give the study 85%
power to detect an increase in adherence of 0.5 standard
deviations (a moderate effect size), with a type 1 error
rate of 5%.
A list of eligible patients that are admitted will be used
as a sampling frame, and patients will be randomly se-
lected from this frame using a computerised program,
and approached to complete the Voil’s. A participation
consent form is available from the corresponding
author.
Characteristics of patients responding in pre and post
collection periods will be compared using independent
sample t-tests (for continuous variables) or chi-square
tests (for categorical variables). Differences in adherence
between patients in the pre period and patients in the
post period will be compared using linear regression
models, adjusting for patient characteristics that may
have changed between the periods.
An economic analysis will consist of a cost-effectiveness
analysis (CEA) and cost-benefit analysis (CBA) [27, 28].
These analyses will be conducted in accordance with
international best-practice for such analyses in health care
including: adoption a health sector perspective; transpar-
ent and scientific methods to identify, measure and value
both costs and outcomes; modelling and uncertainty test-
ing of input parameters; and, interpretation of results
within a broader decision-making framework. The CEA
will answer the question of whether the VCPS is more
cost-effective than compared to treatment as usual; the
CBA will consider the rate of return on investing in the
VCPS. Both analyses will rely on health care utilisation
data outlined in Table 1 that identifies and measures re-
source use associated with the VCPS including: additional
pharmacist time to deliver the intervention; patient and
clinician education; and, any system level changes that
have occurred to facilitate the implementation of the
intervention. Resource use will be collected by the virtual
clinical pharmacist and stored in the patient’s clinical rec-
ord on the eMR as in standard clinical practice. Change in
28 day re-admission will be used as the primary outcome
in the CEA. The CBA will attempt to quantify a wider
range of outcomes associated with the VCPS that can be
valued in monetary terms such as LOS, the cost of treating
adverse events (falls, medication-related errors) and po-
tentially preventable admissions. Monte Carlo analysis will
be used to derive 95% uncertainty intervals for costs and
outcome with results presented in a scatterplot (i.e. cost-
effectiveness plane). The results of the CEA will be consid-
ered in the context of other decision-making criteria such
as: capacity of the intervention to reduce inequity; accept-
ability to stakeholders; feasibility; sustainability; and, po-
tential for other consequences. Results of the CBA will be
expressed as a ratio of benefits to costs whereby a benefit
cost ratio > 1, suggests that the VCPS is a good return on
investment.
A staff focus group will be held at each participating
site 3 months after the beginning of the VCPS transition
period. The focus group will investigate the perceived
acceptability of the service for staff. All staff who work
in clinical areas where the VCPS operates will be asked
to participate in the focus group. Senior staff and man-
agers’ will participate in a separate focus group to all
other staff to take into account potential power relation-
ships that may inhibit the responses of junior staff. The
focus group will be held 3 months after the VCPS com-
mences to provide adequate time for staff to be exposed
to the service. The focus group discussion will explore
the issues, benefits, barriers and overall acceptability of
the VCPS. A participation consent form is available from
the corresponding author.
A qualitative approach will be used to undertake focus
groups with participating staff (n = 25). The focus groups
will investigate implementation processes and those af-
fected by them to understand the context of VCPS im-
plementation [29, 30]. The focus groups will be audio-
recorded, transcribed verbatim and entered into QSR
NVivo. Thematic analysis will be utilised to deductively
and inductively identify barriers and facilitators to the
VCPS implementation. Data files and transcripts will be
stored on a password protected server only accessible by
the research team.
There was no patient or public involvement in the re-
search design. Community consultation with Australian
Indigenous communities in the study sites will be con-
ducted prior to the VCPS implementation to explain the
project and identify and respond to any concerns. Indi-
genous Australian comprise up to 60 % of the popula-
tion in some sites. If community Elders do not support
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the pharmacy service, or the study, Indigenous people
will not be included in the data collection. Indigenous
research team members will conduct the consultations.
Data monitoring committee: A data monitoring com-
mittee has not been formed because there are minimal
risks associated with the study. However, a project gov-
ernance group has been formed that includes academic
and research pharmacists, government clinical practice
and telehealth specialists and local health executives.
This group will meet quarterly and will be responsible
for monitoring the project progress and addressing any
problems that arise.
The study results will be communicated to the funding
body in regular reports. The research team will also seek
to publish the results in peer reviewed journals, and in
newsletters and research snapshots back to the hospital
sites and surrounding communities where the trial took
place. There are no restrictions on publication. Author-
ship eligibility will follow the International Committee of
Medical Journal Editors (ICMJE) guidelines. There are
no plans to grant public access to the participant level
dataset. The full protocol is available from ANZCTR.
Discussion
There is good evidence that hospital based clinical phar-
macy services demonstrate measurable outcomes in re-
ducing preventable admissions to hospital, minimising
medication-related harm, improving medication-related
communication on transfer of care to primary care pro-
viders, empowering patients with a better understanding
of their medications, improve concordance with medica-
tion management and improve evidence-based prescrib-
ing (including antimicrobial stewardship) [7, 8, 15, 21].
However, there is limited quality evidence that similar
outcomes can be achieved through the provision of vir-
tual pharmacy services. This protocol paper describes a
stepped wedge clustered randomised control trial of vir-
tual pharmacy services delivered in eight rural and re-
mote hospitals.
If successful, this project can provide a model for
pharmacy delivery in rural and remote locations. More-
over, this trial has the potential to assist with medication
literacy and concordance amongst Aboriginal patients
who present to participating facilities. All rural and re-
mote Australians, including Aboriginal peoples, have a
shorter life expectancy and a more significant burden of
chronic disease which equates to greater polypharmacy
and a higher risk of medication-related harm [31].
It is widely recognised that clinical pharmacists are
best placed to reduce rates of medication error [6, 7];
however, the workforce is poorly integrated into rural
and remote health facilities [17, 18]. This project will
provide evidence about ways in which the proven bene-
fits of hospital pharmacists can be maximised utilising
telehealth technology. The results of this study may lead
to the development of a proven model of care that could
easily be scaled and implemented in other local health
districts in NSW and Australia.
The pragmatic design and sample of the study also
greatly increases the generalisability by: 1.) using a com-
munity sample; and 2.) using a model that mirrors rou-
tine clinical care with routine data collection to increase
validity, reliability and generalisability of results to other
rural and remote hospital sites.
We also acknowledge the limitations of this trial, in-
cluding: variability of sites, staffing and patient popula-
tions and self-report measures of medication adherence.
First, participating sites are all small rural or remote hos-
pitals with varying numbers and skill sets of staff. While
technology has been well integrated into healthcare
across the region, staff may not be familiar with how to
use it or there could be system failures that prevent the
pharmacy service delivery.
The identified limitations highlight the challenges of
running an RCT of this kind under real-world condi-
tions (e.g. casual staff, working with a diverse population,
etc.). Despite these potential limitations, this trial is one
of the most methodologically rigorous trials of virtual
pharmacy interventions that exists to date. We will make
extensive efforts to control for any sources of potential
bias, imprecision, or multiplicity of analyses. Should
modifications to the protocol be required these will be
updated in the ANZCTR record as soon as they occur
(Appendix).
This paper describes the protocol for a stepped wedge
clustered randomized controlled trial designed to evalu-
ate the effectiveness of a virtual pharmacy service deliv-
ered in eight rural or remote hospital sites. We aim to
demonstrate the effectiveness of pharmacy interventions
for rural populations, and inform best practise for using
virtual healthcare to improve access to pharmacy
services.
Appendix
Data category Information32
Primary registry and trial
identifying number
Australian New Zealand Clinical Trials
Registry (ANZCTR) -ACTRN12619001757101
Registered on
Date of registration in
primary registry
11 December 2019.
Secondary identifying
numbers
NA
Source(s) of monetary or
material support
NSW Ministry of Health, Australia
Primary sponsor NSW Ministry of Health, Australia
Secondary sponsor(s) NA
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Appendix (Continued)
Data category Information32
Contact for public queries Brett Chambers [+ 61,447,482,949] [brett.
chambers@health.nsw.gov.au]
Contact for scientific
queries
Brett Chambers [+ 61,447,482,949] [brett.
chambers@health.nsw.gov.au]
Public title A stepped wedge trial of efficacy and
scalability of a virtual clinical pharmacy
service (VCPS) in rural and remote NSW
health facilities
Scientific title A stepped wedge trial of efficacy and
scalability of a virtual clinical pharmacy
service (VCPS) in rural and remote NSW
health facilities
Countries of recruitment Australia
Health condition(s) or
problem(s) studied
Clinical pharmacy services
Intervention(s) Virtual clinical pharmacy service to rural
and remote hospitals
Key inclusion and
exclusion criteria
Ages eligible for study: ≥18 yearsSexes
eligible for study: bothAccepts healthy
volunteers: noInclusion criteria: adult
patient (≥ 18 years) hospitalised in one of
the study sites requiring medication
reconciliation or other pharmacy
serviceExclusion criteria: Outpatients,
Residential Aged Care, Transitional Aged
Care, Hospital in the Home
Study type InterventionalAllocation:
randomizedIntervention model: Stepped
wedgeMasking: NoPrimary purpose:
treatment
Date of first enrolment April 2020
Target sample size 2088
Recruitment status Recruiting
Primary outcome(s) There are 2 co-primary outcome variables:
1) the proportion of separations (“dis-
charged home by the hospital”) where the
medical reconciliation occurred on admis-
sion; and 2) the proportion of separations
(“discharged home by the hospital”) where
the medical reconciliation occurred on
discharge.
Key secondary outcomes Secondary outcomes will include 28-day re-
admission, hospital length of stay (LOS),
number of falls and detection of
medication-related errors.
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